Publicaciones en colaboración con investigadores/as de University of Cincinnati (16)

2024

  1. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

    Nature Genetics, Vol. 56, Núm. 9, pp. 1878-1889

  2. Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease

    Nature Genetics, Vol. 56, Núm. 1, pp. 27-36

2023

  1. Author Correction: Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2) (npj Parkinson's Disease, (2023), 9, 1, (100), 10.1038/s41531-023-00526-9)

    npj Parkinson's Disease

  2. Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)

    npj Parkinson's Disease, Vol. 9, Núm. 1

2022

  1. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 9, pp. 2367-2374.e3

2021

  1. Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome

    Stroke, Vol. 52, Núm. 1, pp. 132-141

  2. Global impact of COVID-19 on stroke care

    International Journal of Stroke, Vol. 16, Núm. 5, pp. 573-584

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death

    Blood, Vol. 137, Núm. 24, pp. 3351-3364

  5. Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19

    New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802

  6. Toward e-Scales: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales

    Movement Disorders Clinical Practice, Vol. 8, Núm. 2, pp. 208-214

2019

  1. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial

    The Lancet, Vol. 393, Núm. 10175, pp. 1021-1032

  2. Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion

    OncoImmunology, Vol. 8, Núm. 11

2012

  1. International seminar on the red blood cells as vehicles for drugs

    Expert Opinion on Biological Therapy

2006

  1. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: Consensus report and recommendations

    Cancer Research, Vol. 66, Núm. 1, pp. 95-106

1997

  1. Mechanisms of sodium/calcium selectivity in sodium channels probed by cysteine mutagenesis and sulfhydryl modification

    Biophysical Journal, Vol. 72, Núm. 3, pp. 989-996